IMPACT STUDY

Recruiting to September 2022

Aim: This study aims to evaluate the effect of IMCY-0098 on the immune signature (treatment-specific biomarkers), and the effect of the study drug upon the preservation of beta-cell function in  adult patients with Type 1 Diabetes. Further safety data will also be collected.

What will taking part involve?

  • Going to one of the study locations eleven times over the course of a year, including screening and randomisation visits.
  • The main study (for patients who are HLA DR4 positive) will include receiving a dose of either the treatment being studied, or a placebo every two weeks, from randomisation to week 10, six times in total.
  • The sub-study (for patients who are HLA DR4 negative, but HLA DR3 positive) will include receiving a dose of the treatment being studied, every 2 weeks from randomisation to week 10, six times in total.
  • For both the main study and sub-study, a ‘booster’ dose of the same treatment will be given 24 weeks after the first treatment.

Contact the study directly:

Email: T1D Consortium


DIABETIC TWIN STUDY

Currently Recruiting

Aim: To study the influence of environment and genes on the onset of type 1 diabetes using identical twins.

What will taking part involve?

You will be asked to give a blood sample and a mouth swab sample, and you will be asked about your health

Contact the study directly:

Call: 020 7882 2365 Dr Mohammed Hawa, Study Manager
Email: m.i.hawa@qmul.ac.uk



Ver-A-T1D STUDY

Recruiting to November 2022

Aim: Verapamil, a known blood pressure lowering drug, has been shown recently to protect and strengthen beta cells and slows down beta cell destruction in Type 1 diabetes. The aim is to confirm the effect of 360mg Verapamil sustained release (SR) administered orally once daily (titrated over the first 3 months from 120 mg to 360 mg).

What will taking part involve?

  • Those who take part will be asked to attend a study visit for screening, then take a tablet once a day for 1 year which will either be Verapamil or a placebo.
  • There will be seven treatment visits and three phone visits during this time with different tests taken, and an optional follow up visit at 2 years.

Contact the study directly:

Email: T1D Consortium


DROPLeT STUDY

Recruiting to December 2021

Aim: The aim of this research is to find out if older adults (aged over 30) with Type 1 diabetes have similar rates of progression to young adults (aged under 30).

What will taking part involve?

  • The study can be completed entirely from home, with the equipment sent to you and samples returned by post.
  • On 3 occasions you will be asked to fast overnight and collect blood samples before and after a liquid meal, and you will be asked to wear a Continuous Glucose Monitor for the year and optionally provide weekly fingerprick blood samples.

Contact the study directly:

Call 01392 408184 or email:  rde-tr.DiabetesResearch@nhs.net


Extod-Immune

Recruiting to: April 2023

Summary

The project is for patients with type-1 diabetes (diagnosed within 1 year) who are not physically active. Patients will be asked to undertake an exercise intervention for 12 weeks in their own home, followed by a 12-week control period with no prescribed exercise.

Aim   

The aim of this project is to investigate the impact of a remotely monitored exercise intervention on immune driven disease activity in patients with a recent diagnosis of type-1 diabetes vs. standard care with no prescribed exercise.

Contact us
Email: extod-immune@contacts.bham.ac.uk

MELD-ATG

Recruiting to: Nov 2022  

Aim
People develop Type 1 diabetes (T1D) because their immune system, the part of the body which helps fight infections, mistakenly attacks and destroys the insulin-producing cells in the pancreas (beta cells). When the immune system destroys these cells, the body’s ability to produce insulin decreases, blood glucose levels run high, and T1D develops.

 At the time of diagnosis of T1D, there are usually a small number of beta cells (10-20%) left in the pancreas, which still produce small amounts of insulin. We call this level of activity “beta cell function”. Most people with T1D will eventually stop producing insulin themselves. This may occur rapidly in a few months, or more slowly over several years. However, the longer people with T1D can produce their own insulin, the better it is for the control of blood glucose levels and to avoid long-term complications.

Previous research has shown that a drug called anti-thymocyte globulin (ATG) may help prevent the immune system from attacking and destroying the insulin-producing beta cells. In the MELD-ATG trial, we are looking for the minimum effective low doseof ATG in young people newly diagnosed with T1D that:

  • Can slow the decline of beta cell function and preserve the body’s own insulin production
  • Has manageable side effects

What Will Taking Part Involve?

Participation will involve 8-10 hospital/clinic visits over about 13 months, and some at-home collections. Most visits take 1-4 hours. Treatment is given over two consecutive days and includes one overnight stay for most participants.

Contact us
Call:

Email:  MELD-ATG@medschl.cam.ac.uk

CFZ533 Study

Recruiting to: June 2024

Aim
Clinical study of a new medication called CFZ533 (or iscalimab) in children and young adults aged 6-21 years with newly diagnosed Type 1 diabetes.
By administering CFZ533 soon after T1DM starts, it is thought that it may be possible to slow or stop destruction of the remaining insulin-producing beta cells in the pancreas, and so preserve remaining insulin production.

What will taking part involve?
• After an initial screening visit to collect data, you will be asked to attend a hospital visit every 4 weeks for around a year.
• You will receive either the CFZ533 drug or a dummy drug (also known as ‘placebo’), with the first dose being given by intravenous injection and subsequent doses being given subcutaneously, decided at random by a special computer programme.
• This will be ‘blinded’ which means no one knows if its CFZ533 or placebo (though this can be found out in an emergency).
• You will be assessed during the study in several ways: physical examinations, blood and urine samples, study diaries, continuous glucose monitoring and tests to see how well the body deals with a meal.

Contact the study directly:
Please see the CFZ533X2207 study page on the Type 1 Diabetes UK Consortium website – once on the T1D UK website, you can request further information about the study by clicking the ‘get involved’ button. (Please be reassured that requesting further information does not commit you to taking part in the study).